CBSC secures Health Canada license for CardioHolter AT with $375K order from Your Heart Protector Corp, expanding cardiac monitoring in Canada.

心脏生物科技解决方案获得加拿大卫生部MyCardia AT设备许可证

CBSC secures Health Canada license for CardioHolter AT, lands $375K order with Your Heart Protector Corp, expanding into Canadian market.

CBSC announces $375,000 Noventis Medical purchase order and new recurring revenue program for MyCardia AT cardiac monitoring devices.

CBSC宣布37.5万美元采购订单及循环收入项目

CBSC secures $375K purchase order with Noventis Medical and launches recurring revenue program for MyCardia AT devices.

Cardiac Biotech Solutions signs exclusive $600K Noventis Medical distribution agreement for Latin America.

心脏生物科技解决方案(CBSC)签署覆盖中美洲和南美洲的独家五年分销协议

Cardiac Biotech Solutions, Inc. signs $600K exclusive distribution deal with Noventis Medical, expanding cardiac monitoring reach into Latin America.

正式发布新一代MyCardia AT心脏监测仪

CB Scientific, Inc. (CBSC) has officially launched its next-generation MyCardia AT cardiac event monitor in collaboration with Datrix, LLC. Designed for enhanced remote cardiac monitoring, the FDA-cleared device offers a lightweight, easy-to-use design with seamless integration into the MyCardia app ecosystem. The MyCardia AT monitor enables early detection of cardiac arrhythmias, helping physicians diagnose transient heart conditions more effectively. The device is set to roll out across SE Asia, Hong Kong, Macau, and pending regulatory approvals, Canada and China.

How can we help you?

Tell us what you are interested in.

订阅我们的新闻邮件!

订阅我们的电子报,我们将直接向您发送最新消息。